GLP-1 receptor agonists (like semaglutide, sold as Ozempic or Rybelsus) work by mimicking a gut hormone that helps regulate blood sugar, suppress appetite, and promote weight loss
For the first time, revenue from innovative drugs and licensing made up over 60% of total income
14 Liraglutide and semaglutide, originally developed for people with Type 2 diabetes mellitus (T2DM), are approved for chronic weight management in people with obesity (or overweight and 1 weight-related comorbidities
An overall benefit of the family of GLP-1RAs was in weight management
GLP-1 (Glucagon-like peptide-1)...Acts on the hypothalamus (satiety center) in the brain to suppress appetite GIP (Glucose-dependent insulinotropic polypeptide)...Promotes the secretion of glucagon, which in addition to insulin, promotes fat breakdown and suppresses appetite Feeling full after a meal is due to the secretion of GLP-1 and GIP